Concerns have been raised that universal availability of antiretroviral agents in resource-
In Brazil standard of care highly active antiretroviral therapy (HAART) regimens are freely available to human immunodeficiency virus type 1 (HIV-1)-infected subjects through the national health care system since 1996, as part of a remarkable response against the epidemic (Marins et al. 2003 , Teixeira et al. 2004 ). Universal access to antiretroviral drugs requires an uninterrupted effort to ensure adequate adherence and continued surveillance on the prevalence of resistant strains in the community. Concerns have been raised that widespread availability of antiretroviral drugs in resource-poor settings might lead to the emergence and spread of resistant variants due to suboptimal compliance. Up to the present time, this seems not to be the case in Brazil . When compared to figures reported from developed nations, most studies from Brazil have found relatively low rates of primary HIV-1 drug resistance (Brindeiro et al. 1999 , Dumans et al. 2002 , Brindeiro et al. 2003 , Pires et al. 2004 , Brigido et al. 2005 , Barreto et al. 2006 , Medeiros et al. 2006 , Rodrigues et al. 2006 , SaFerreira et al. 2007 , even though isolated surveys recently reported worrisome rates in the port cities of Santos (Sucupira et al. 2007 ) and Salvador (Pedroso et al. 2007) . Also, resistance rates in Brazil are being reported from studies primarily based in large urban centers and little is known about the prevalence of resistant strains in innermost parts of the country. Since the AIDS epidemic is a growing problem in relatively small Brazilian cities (Szwarcwald et al. 2000 , Eyer-Silva & Morgado 2006 , Eyer-Silva et al. 2007a , where standard of care HAART combinations are also universally available, it will be essential to study the prevalence of resistance-associated mutations in such settings. To the best of our knowledge, a previous report from our group is the sole study addressing this issue that has been published to date in peer reviewed journals .
To further expand our knowledge in this field, we present herein the results of a cross-sectional survey on the prevalence of mutations associated with antiretroviral drug resistance among patients receiving care in two small cities of inner state of Rio de Janeiro, Southeast Brazil: Saquarema and Santo Antonio de Pádua. Since these cities have been assigned relatively low human development index values (http://www.ipea.gov.br/), the present study is an opportunity to assess the prevalence of resistant strains and the efficacy of antiretroviral therapy in relatively underprivileged settings in Brazil with widespread access to standard of care HAART regimens. Silva et al. 2007a, b) .
PATIENTS, MATERIALS AND METHODS

Saquarema
After signed informed consent, blood samples were collected, DNA was extracted from peripheral blood mononuclear cells (PBMC), and the sequence of a single fragment of HIV-1 polymerase gene encompassing the whole protease (PR) and reverse transcriptase (RT) amino acids 1-230 was generated using a previously described in-house protocol Eyer-Silva and Morgado (2005) . All sequences generated were subjected to quality control measures to ensure there were no sample mix-ups or contamination (Learn et al. 1996) . Drug susceptibility level was inferred by submitting the FASTA files of generated strains to the on-line drug resistance interpretation system available at the Stanford HIV resistance database website (http://hivdb.stanford.edu). The Stanford HIV database algorithm then assigns a drug resistance score for each mutation, which is translated into five levels of inferred antiretroviral resistance: susceptible, potential low-level, low-level, intermediate and high-level resistance. In the present report, secondary PR inhibitor mutations known to occur as natural polymorphisms are not reported, even if it is known that they may also contribute to resistance when present with other mutations. Subtyping and recombination analyses were performed by applying maximum likelihood phylogenetic reconstructions and the bootscanning method, as previously described (Eyer-Silva & Morgado 2006) . The study protocol was reviewed and approved by the Ethics Review Board at Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro. The nucleotide sequences of HIV-1 polymerase sequences reported in this study were deposited in the GenBank database under accession numbers DQ899698 through DQ899727 and EF042627 through EF042690.
RESULTS
Between the years of 2004 and 2006 a total of 120 HIV-1 infected patients received care in the municipal HIV-1/AIDS programs of the two cities. Sequences generated from samples of 95 (79%) of these patients (91 adult and 4 pediatric cases) were available for phylogenetic and genotypic analyses. Seventy-seven sequences (81%) were assigned subtype B. The remaining strains were assigned subtypes F1 (8 strains; 8.4%), CRF02_AG (2 strains; 2.1%), D (1 strain; 1%), and unique BF1 recombinants (7 strains; 7.4%). Table I presents the prevalence of mutations known to confer reduced drug susceptibility in the 95 studied subjects. Fifty samples were from treatment-naïve subjects and 45 from antiretroviral-experienced patients. Among the latter, 38 were on HAART regimens as of sampling and seven were off-treatment due to diverse reasons such as non-compliance, transient treatment interruption due to adverse events, and previous vertical transmission prophylaxis which was withhold after delivery.
Among 50 strains recovered from drug naïve patients, we found RT inhibitor-associated mutations in seven (14%), including one strain (2%) with intermediatelevel resistance (06BRSQ-94), five strains with potential low-level resistance and one sequence (05BRSQ-83_P) which harbored the V118I mutation and was considered susceptible to NRTI (Table II) . Table III presents the clinical, epidemiological, and virological data of the 45 treatment-experienced patients. Among seven patients with prior antiretroviral exposure but who were off treatment as of sampling, two (28.5%) harbored strains with reduced drug susceptibility. These mutations were K103N (strain 05BRSQ-21) and M184V (05BRSQ-33). Both these patients were off treatment due to non-compliance.
Among 38 patients on therapy (between 3 months and 10 years) as of sampling, 28 (73.7%) had PVL below de- (5), which lead to removal of nucleoside RT inhibitors (NRTI) already incorporated in the growing DNA chain; mutation M184V (5), which causes resistance due to sterical inhibition to NRTI; and mutations associated with non-nucleoside RT inhibitors (NNRTI) resistance, such as K103N (3), Y181C (1), Y188L (1), and G190A (2). Multinucleoside resistance mutations of the Q151M complex and insertions at codon 69 were not found. Recorded primary mutations to PR inhibitors were L24I (1), D30N (1), L33F (2), I54V (1), V82A (1), and N88D (1). Genotypic patterns clearly suggestive of non-adherence or drug pharmacokinetic failure were found in at least three patients on treatment: strains 04BRSQ-39 and 05BRSQ-70 were recovered from patients on virologic failure, yet no resistance mutations were detected; the patient carrying sequence 05BRSQ-15 was on virologic failure besides no mutation to his current regimen was detected (Table III) . In contrast, three patients had PVL levels below detection limits besides the presence of mutations RT-M184V (04BRSAP01), RT-T215Y (04BRSAP07), and PR-L33F (04BRSQ-06). These three patients were on highly active, lopinavir-including regimens.
DISCUSSION
The present study is the largest analysis of the prevalence of antiretroviral resistance among treatment-naïve and experienced patients followed in small Brazilian cities with universal availability of standard of care HAART regimens. Since we wished to study all patients (regardless of treatment history), including those with PVL below detection limit, we chose to perform resistance testing by targeting HIV-1 DNA from the PBMC proviral compartment, instead of the most commonly used plasma HIV-1 RNA. Although studies have found that the detection of resistance mutations in the HIV-1 RNA plasma compartment may precede that in PBMC (Kaye et al. 1995 , Bi et al. 2003 , it has been shown that HIV DNA recovered from the proviral compartment can reliably be used in drug resistance genotyping (Devereux et al. 2000 , Sarmati et al. 2003 , Chew et al. 2005 , Parisi et al. 2007 , Vicenti et al. 2007 ). In addition, proviral sequences can be useful to detect archived mutations that can compromise future therapeutic options, such as those selected by previously used regimens (Sarmati et al. 2003, SG Parisi et al. unpublished observations) , and have been found to have greater sensitivity after treatment interruption in treatment experienced patients (Venturi et al. 2002) . In fact, in this study we demonstrate the occurrence of previously selected resistance mutations in three patients with PVL bellow detection limit (04BRSAP01, 04BRSAP07, 04BRSQ-06) and two patients who were off-treatment as of sampling (05BR-SQ-21, 05BRSQ-33). Proviral sequences also allow genotyping analysis in patients with low to undetectable PVL and may be useful in such patients when a change in the antiretroviral combination is being considered due to toxicity or when a simplified regimen is necessary.
A total of four group M subtypes (B, D, F1, CRF02_ AG) and several unique BF1 recombinants were uncovered in this survey. The demonstration of such a molecular diversity in these two small, inner cities further highlights the complexity of the HIV-1 epidemic in Brazil. An overall low prevalence of mutations conferring antiretroviral resistance was found in both treatmentnaïve and experienced patients. The prediction of drug susceptibility found that one out of 50 (2%) strains recovered from drug-naïve subjects had intermediate-level resistance to thymidine analog RT inhibitors (with lowlevel resistance to abacavir, didanosine, and tenofovir). This strain (sequence 06BRSQ-94) harbored one established drug-resistance mutation (D67N) associated with two additional mutations at established drug-resistance positions: K70S and T215D. Mutation K70S has already been recorded under a stavudine plus didanosine combination, in a patient with previous exposure to zidovudine and lamivudine (Lawrence et al. 1999) . Mutation T215D has been described in drug-naïve subjects as a non-wild type revertant of mutations T215Y or T215F (Miller et al. 2000) . In the Stanford HIV resistance database (http:// cpr.stanford.edu/cpr/), T215D mutation is present in 0.2% and 0.7% of sequences recovered from drug-naïve and drug-treated patients, respectively. T215D mutation seems to emerge due to fitness advantage and is fully susceptible to NRTI, yet their presence leads to faster reappearance of resistant 215 viruses under the pressure of thymidine analogues (Garcia-Lerma et al. 2001 , Violin et al. 2004 . This implies that a strain with intermediate resistance to thymidine analogs has been transmitted or that prior antiretroviral therapy was deliberately omitted. Six additional strains from drug-naïve subjects harbored mutations known to be associated with resistance to RT inhibitors. Sequence 05BRSQ-83_P presented mutation V118I, which occurs in around 2% of untreated subjects and has been described in treatment-naïve Brazilian patients (Dumans et al. 2002 , Brindeiro et al. 2003 . This strain was predicted as susceptible to RT inhibitors. Four strains (05BRSAP26, 05BRSAP28, 06BRSAP31, and 06BRSAP33) harbored the polymorphism V179D, which occurs in 3.1% of subtype B-infected drug-naïve subjects and causes potential low-level resistance to each available NNRTI (Rhee et al. 2005) . Phylogenetic analyses (data not shown) demonstrated that these four strains form a strong monophylectic cluster and were recovered from patients who probably took part in the same chain of viral spread. Whether this intriguing cluster from the city of Santo Antonio de Pádua represents a reservoir of a variant with natural resistance to NNRTI and with potential to spread is unknown. Strain 06BRSAP30 presented the T69N mutation, which poses potential lowlevel resistance to several NRTI (Winters & Merigan 2001 ). This mutation is by far the most common nonaspartic acid change at codon 69 (Winters & Merigan 2001) and has also been reported from drug-naïve Brazilian patients (Pires et al. 2004) .
Among 38 patients who were on antiretroviral combinations as of sampling, 28 (73.7%) had PVL below detection limits (26 of whom without evidence of resistance mutations). Only two strains harbored resistance mutations to both RT and PR inhibitors. Although three strains presented a genotypic pattern suggestive of nonadherence (or drug pharmacokinetic failure), the overall figures stand for a high rate of success of antiretroviral therapy in these real-life underprivileged settings.
The present study has a number of limitations. Traditional population-based sequencing may not consistently detect minor drug-resistant variants and thus may be insensitive to strains resistant to previously used drugs and to detect decayed resistant variants transmitted to untreated subjects. A comprehensive panel of strains could only be detected by extensive clonal sequencing from a polymerase chain reaction product. As already discussed, targeting the plasma viral compartment may reveal resistant variants not yet abundant within circulating PBMC. The overall number of studied subjects is limited, as well as the geographic span of the survey.
The relatively high frequency of plasma viral load below detection limits among patients on treatment and the overall low prevalence of mutations associated with reduced drug susceptibility presented herein are reassuring and in accordance with a previous, smaller survey carried out by our group in another small city in state of Rio de Janeiro . Nevertheless, the continued widespread access to antiretroviral combinations in Brazil, including in relatively small cities from the innermost parts of the country, needs to be accompanied by an uninterrupted effort to ensure adherence and regular, comprehensive surveys on the prevalence of resistant strains in the community.
